These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 21698649)

  • 1. CINRG pilot trial of coenzyme Q10 in steroid-treated Duchenne muscular dystrophy.
    Spurney CF; Rocha CT; Henricson E; Florence J; Mayhew J; Gorni K; Pasquali L; Pestronk A; Martin GR; Hu F; Nie L; Connolly AM; Escolar DM;
    Muscle Nerve; 2011 Aug; 44(2):174-8. PubMed ID: 21698649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CINRG pilot trial of oxatomide in steroid-naïve Duchenne muscular dystrophy.
    Buyse GM; Goemans N; Henricson E; Jara A; van den Hauwe M; Leshner R; Florence JM; Mayhew JE; Escolar DM
    Eur J Paediatr Neurol; 2007 Nov; 11(6):337-40. PubMed ID: 17459739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study.
    Smith EC; Conklin LS; Hoffman EP; Clemens PR; Mah JK; Finkel RS; Guglieri M; Tulinius M; Nevo Y; Ryan MM; Webster R; Castro D; Kuntz NL; Kerchner L; Morgenroth LP; Arrieta A; Shimony M; Jaros M; Shale P; Gordish-Dressman H; Hagerty L; Dang UJ; Damsker JM; Schwartz BD; Mengle-Gaw LJ; McDonald CM;
    PLoS Med; 2020 Sep; 17(9):e1003222. PubMed ID: 32956407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pentoxifylline as a rescue treatment for DMD: a randomized double-blind clinical trial.
    Escolar DM; Zimmerman A; Bertorini T; Clemens PR; Connolly AM; Mesa L; Gorni K; Kornberg A; Kolski H; Kuntz N; Nevo Y; Tesi-Rocha C; Nagaraju K; Rayavarapu S; Hache LP; Mayhew JE; Florence J; Hu F; Arrieta A; Henricson E; Leshner RT; Mah JK
    Neurology; 2012 Mar; 78(12):904-13. PubMed ID: 22402864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucocorticoid corticosteroids for Duchenne muscular dystrophy.
    Manzur AY; Kuntzer T; Pike M; Swan A
    Cochrane Database Syst Rev; 2008 Jan; (1):CD003725. PubMed ID: 18254031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Knee Strength and Ankle Range of Motion Impacts on Timed Function Tests in Duchenne Muscular Dystrophy: In the Era of Glucocorticoids.
    Duong T; Canbek J; Fernandez-Fernandez A; Henricson E; Birkmeier M; Siener C; Tesi Rocha C; McDonald C; Gordish-Dressman H;
    J Neuromuscul Dis; 2022; 9(1):147-159. PubMed ID: 34719507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucocorticoid corticosteroids for Duchenne muscular dystrophy.
    Manzur AY; Kuntzer T; Pike M; Swan A
    Cochrane Database Syst Rev; 2004; (2):CD003725. PubMed ID: 15106215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment with L-citrulline and metformin in Duchenne muscular dystrophy: study protocol for a single-centre, randomised, placebo-controlled trial.
    Hafner P; Bonati U; Rubino D; Gocheva V; Zumbrunn T; Gueven N; Fischer D
    Trials; 2016 Aug; 17(1):389. PubMed ID: 27488051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of glucocorticoids and idebenone on respiratory function in patients with duchenne muscular dystrophy.
    Buyse GM; Goemans N; van den Hauwe M; Meier T
    Pediatr Pulmonol; 2013 Sep; 48(9):912-20. PubMed ID: 23129412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liquid formulation of pentoxifylline is a poorly tolerated treatment for duchenne dystrophy.
    Zimmerman A; Clemens PR; Tesi-Rocha C; Connolly A; Iannaccone ST; Kuntz N; Arrieta A; Hache L; Henricson E; Hu F; Mayhew J; Escolar DM
    Muscle Nerve; 2011 Aug; 44(2):170-3. PubMed ID: 21674534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Idebenone as a novel, therapeutic approach for Duchenne muscular dystrophy: results from a 12 month, double-blind, randomized placebo-controlled trial.
    Buyse GM; Goemans N; van den Hauwe M; Thijs D; de Groot IJ; Schara U; Ceulemans B; Meier T; Mertens L
    Neuromuscul Disord; 2011 Jun; 21(6):396-405. PubMed ID: 21435876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medical management of muscle weakness in Duchenne muscular dystrophy.
    Rivera SR; Jhamb SK; Abdel-Hamid HZ; Acsadi G; Brandsema J; Ciafaloni E; Darras BT; Iannaccone ST; Konersman CG; Kuntz NL; McDonald CM; Parsons JA; Tesi Rocha C; Zaidman CM; Butterfield RJ; Connolly AM; Mathews KD
    PLoS One; 2020; 15(10):e0240687. PubMed ID: 33075081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Daily prednisone treatment in Duchenne muscular dystrophy in southwest China.
    Hu J; Ye Y; Kong M; Hong S; Cheng L; Wang Q; Qin J; Zou L; Jiang L
    Muscle Nerve; 2015 Dec; 52(6):1001-7. PubMed ID: 25809413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy.
    Escolar DM; Hache LP; Clemens PR; Cnaan A; McDonald CM; Viswanathan V; Kornberg AJ; Bertorini TE; Nevo Y; Lotze T; Pestronk A; Ryan MM; Monasterio E; Day JW; Zimmerman A; Arrieta A; Henricson E; Mayhew J; Florence J; Hu F; Connolly AM
    Neurology; 2011 Aug; 77(5):444-52. PubMed ID: 21753160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cooperative international neuromuscular research group Duchenne natural history study: glucocorticoid treatment preserves clinically meaningful functional milestones and reduces rate of disease progression as measured by manual muscle testing and other commonly used clinical trial outcome measures.
    Henricson EK; Abresch RT; Cnaan A; Hu F; Duong T; Arrieta A; Han J; Escolar DM; Florence JM; Clemens PR; Hoffman EP; McDonald CM;
    Muscle Nerve; 2013 Jul; 48(1):55-67. PubMed ID: 23649481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biochemical rationale and the cardiac response of patients with muscle disease to therapy with coenzyme Q10.
    Folkers K; Wolaniuk J; Simonsen R; Morishita M; Vadhanavikit S
    Proc Natl Acad Sci U S A; 1985 Jul; 82(13):4513-6. PubMed ID: 3859873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative assessment of the T2 relaxation time of the gluteus muscles in children with Duchenne muscular dystrophy: a comparative study before and after steroid treatment.
    Kim HK; Laor T; Horn PS; Wong B
    Korean J Radiol; 2010; 11(3):304-11. PubMed ID: 20461184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment effect of idebenone on inspiratory function in patients with Duchenne muscular dystrophy.
    Buyse GM; Voit T; Schara U; Straathof CS; D'Angelo MG; Bernert G; Cuisset JM; Finkel RS; Goemans N; Rummey C; Leinonen M; Mayer OH; Spagnolo P; Meier T; McDonald CM;
    Pediatr Pulmonol; 2017 Apr; 52(4):508-515. PubMed ID: 27571420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving clinical trial design for Duchenne muscular dystrophy.
    Merlini L; Sabatelli P
    BMC Neurol; 2015 Aug; 15():153. PubMed ID: 26306629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial.
    Mortensen SA; Rosenfeldt F; Kumar A; Dolliner P; Filipiak KJ; Pella D; Alehagen U; Steurer G; Littarru GP;
    JACC Heart Fail; 2014 Dec; 2(6):641-9. PubMed ID: 25282031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.